Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label,
proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and …

Cellular senescence has been identified as a pathological mechanism linked to tau and
amyloid beta (Aβ) accumulation in mouse models of Alzheimer's disease (AD). Clearance of …

Preclinical studies indicate an age-associated accumulation of senescent cells across
multiple organ systems. Emerging evidence suggests that tau protein accumulation, which …

The recent FDA-approval for amyloid lowering therapies reflects an unwavering commitment
from the Alzheimer's disease (AD) research community to identify treatments for this leading …

Neuritic plaques, a pathological hallmark in Alzheimer's disease (AD) brains, comprise
extracellular aggregates of amyloid-beta (Aβ) peptide and degenerating neurites that …

Background Senescent cells, which can release factors that cause inflammation and
dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with …

Cellular senescence and the hallmarks of aging contribute to age-related disease and
dysfunction. The Unitary Theory of Fundamental Aging Mechanisms highlights the …

We examine similar and differential effects of two senolytic treatments, ABT‐263 and
dasatinib+ quercetin (D+ Q), in preserving cognition, markers of peripheral senescence, and …

Physical function declines in old age, portending disability, increased health expenditures,
and mortality. Cellular senescence, leading to tissue dysfunction, may contribute to these …

Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic
drugs Dasatinib, Quercetin, Fisetin and Navitoclax were discovered using a hypothesis …